Published in Liver Transpl on April 01, 2009
Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus. Hepatology (2010) 1.59
Recipient-donor race mismatch for African American liver transplant patients with chronic hepatitis C. Liver Transpl (2012) 1.54
Genetic diversity of the KIR/HLA system and susceptibility to hepatitis C virus-related diseases. PLoS One (2015) 1.50
Effect of killer immunoglobulin-like receptors in the response to combined treatment in patients with chronic hepatitis C virus infection. J Virol (2010) 1.15
Decreased infections in recipients of unrelated donor hematopoietic cell transplantation from donors with an activating KIR genotype. Biol Blood Marrow Transplant (2010) 0.96
NK cells, innate immunity and hepatitis C infection after liver transplantation. Clin Infect Dis (2011) 0.86
The Role of FGL2 in the Pathogenesis and Treatment of Hepatitis C Virus Infection. Rambam Maimonides Med J (2010) 0.83
Post-liver transplant hepatitis C virus recurrence: an unresolved thorny problem. World J Gastroenterol (2014) 0.83
The natural killer cell response to HCV infection. Immune Netw (2013) 0.82
Comparative analysis of NK-cell receptor expression and function across primate species: Perspective on antiviral defenses. Self Nonself (2010) 0.79
Natural killer cells play divergent roles in shaping the outcome of hepatitis C virus recurrence following liver transplantation. Liver Transpl (2009) 0.77
Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol (2003) 5.17
Long-term outcome of renal transplantation from older donors. N Engl J Med (2006) 5.10
Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety. Hepatology (2010) 3.53
Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat Genet (2009) 3.33
Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol (2006) 3.09
A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. Gastroenterology (2004) 2.70
Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol (2006) 2.61
SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology (2009) 2.45
Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol (2008) 2.36
Management of nonneoplastic portal vein thrombosis in the setting of liver transplantation: a systematic review. Transplantation (2012) 2.26
Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review. Transpl Int (2014) 2.26
The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available? J Hepatol (2004) 2.18
Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study. Lancet Oncol (2011) 2.04
A randomized study comparing ligation with propranolol for primary prophylaxis of variceal bleeding in candidates for liver transplantation. Liver Transpl (2007) 2.01
Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology (2006) 1.92
A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology (2009) 1.90
Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg (2004) 1.88
Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis. Liver Int (2012) 1.87
A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol (2007) 1.83
A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. Hepatology (2009) 1.78
Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood (2002) 1.77
Report of the Paris consensus meeting on expanded criteria donors in liver transplantation. Liver Transpl (2008) 1.75
Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study. Liver Transpl (2007) 1.68
Liver transplantation for acute liver failure in Europe: outcomes over 20 years from the ELTR database. J Hepatol (2012) 1.66
Common variants in P2RY11 are associated with narcolepsy. Nat Genet (2010) 1.65
Beyond "cirrhosis": a proposal from the International Liver Pathology Study Group. Am J Clin Pathol (2012) 1.65
Insulin resistance and necroinflammation drives ductular reaction and epithelial-mesenchymal transition in chronic hepatitis C. Gut (2010) 1.59
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation (2016) 1.59
Influence of steroids on HCV recurrence after liver transplantation: A prospective study. J Hepatol (2007) 1.56
ImmunoChip study implicates antigen presentation to T cells in narcolepsy. PLoS Genet (2013) 1.55
An updated follow-up of chronic hepatitis C after three decades of observation in pediatric patients cured of malignancy. Pediatr Blood Cancer (2010) 1.55
Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching. Dig Liver Dis (2010) 1.54
The survival benefit of liver transplantation in hepatocellular carcinoma patients. Dig Liver Dis (2010) 1.53
Kaposi's sarcoma in transplant and HIV-infected patients: an epidemiologic study in Italy and France. Transplantation (2005) 1.52
Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease. Gastroenterology (2008) 1.52
The homeostasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients. Liver Int (2010) 1.51
Double-blind comparison of hepatitis C histological recurrence Rate in HCV+ Liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine. Transplantation (2004) 1.49
Reduced serum hepcidin levels in patients with chronic hepatitis C. J Hepatol (2009) 1.48
Human leukocyte antigen crossmatch testing is important for liver retransplantation. Liver Transpl (2010) 1.48
Mutations in DNMT1 cause autosomal dominant cerebellar ataxia, deafness and narcolepsy. Hum Mol Genet (2012) 1.48
Solid-papillary tumors of the pancreas: histopathology. JOP (2006) 1.47
Three-yr safety and efficacy of everolimus and low-dose cyclosporine in de novo pediatric kidney transplant patients. Pediatr Transplant (2014) 1.44
Management of chronic hepatitis C in childhood: the impact of therapy in the clinical practice during the first 2 decades. Dig Liver Dis (2010) 1.42
Liver transplantation for unresectable hepatocellular carcinoma in normal livers. J Hepatol (2012) 1.42
Skin cancer and other cutaneous disorders in liver transplant recipients. Acta Derm Venereol (2012) 1.41
Development and validation of a questionnaire evaluating the impact of hepatitis B immune globulin prophylaxis on the quality of life of liver transplant recipients. Liver Transpl (2012) 1.41
Liver transplantation using suboptimal grafts: impact of donor harvesting technique. Liver Transpl (2007) 1.41
Human leukocyte antigen polymorphisms in Italian primary biliary cirrhosis: a multicenter study of 664 patients and 1992 healthy controls. Hepatology (2008) 1.40
Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern Europe. Eur J Cancer (2007) 1.40
Complex movement disorders at disease onset in childhood narcolepsy with cataplexy. Brain (2011) 1.35
Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B. World J Gastroenterol (2007) 1.34
CD105(+) cells from Wharton's jelly show in vitro and in vivo myogenic differentiative potential. Int J Mol Med (2006) 1.34
Human skin-derived stem cells migrate throughout forebrain and differentiate into astrocytes after injection into adult mouse brain. J Neurosci Res (2004) 1.33
Epitopes of human leukocyte antigen class I antibodies found in sera of normal healthy males and cord blood. Hum Immunol (2009) 1.29
Predictors of hypocretin (orexin) deficiency in narcolepsy without cataplexy. Sleep (2012) 1.28
Predictors of long-term survival after liver transplantation for hepatocellular carcinoma. Am J Gastroenterol (2005) 1.28
Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study. Hepatology (2006) 1.27
Analysis of liver repair mechanisms in Alagille syndrome and biliary atresia reveals a role for notch signaling. Am J Pathol (2007) 1.26
Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology (2006) 1.24
Searching for a marker of REM sleep behavior disorder: submentalis muscle EMG amplitude analysis during sleep in patients with narcolepsy/cataplexy. Sleep (2008) 1.22
Polyomavirus BK-specific immunity after kidney transplantation. Transplantation (2004) 1.22
Anticoagulation for the treatment of thrombotic complications in patients with cirrhosis. Liver Int (2012) 1.21
Chronic hepatitis C virus infection in childhood: clinical patterns and evolution in 224 white children. Clin Infect Dis (2003) 1.18
beta-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. Liver Int (2009) 1.17
Incidence of cancer after kidney transplant: results from the North Italy transplant program. Transplantation (2003) 1.14
Systemic efficacy of combined suicide/cytokine gene therapy in a murine model of hepatocellular carcinoma. J Hepatol (2005) 1.13
Neurologic complications after solid organ transplantation. Transpl Int (2008) 1.12
Cryoglobulinemia. Blood Rev (2007) 1.11
Post-load insulin resistance does not predict virological response to treatment of chronic hepatitis C patients without the metabolic syndrome. Dig Liver Dis (2012) 1.10
Clinical, polysomnographic and genome-wide association analyses of narcolepsy with cataplexy: a European Narcolepsy Network study. J Sleep Res (2013) 1.07
Blood group genotyping for Jk(a)/Jk(b), Fy(a)/Fy(b), S/s, K/k, Kp(a)/Kp(b), Js(a)/Js(b), Co(a)/Co(b), and Lu(a)/Lu(b) with microarray beads. Transfusion (2007) 1.07
A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer (2010) 1.06
Is percutaneous radiofrequency thermal ablation of hepatocellular carcinoma a safe procedure? Eur J Gastroenterol Hepatol (2008) 1.05
Daytime continuous polysomnography predicts MSLT results in hypersomnias of central origin. J Sleep Res (2012) 1.04
Nocturnal rapid eye movement sleep latency for identifying patients with narcolepsy/hypocretin deficiency. JAMA Neurol (2013) 1.02
The long-term prognosis of renal transplantation in patients with lupus nephritis. Am J Kidney Dis (2005) 1.02
Summary of candidate selection and expanded criteria for liver transplantation for hepatocellular carcinoma: a review and consensus statement. Liver Transpl (2011) 1.02
Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up-to-seven criteria. Liver Transpl (2009) 1.02
Cytokines and liver failure: modification of TNF- and IL-6 in patients with acute on chronic liver decompensation treated with Molecular Adsorbent Recycling System (MARS). Acta Biomed (2003) 1.00
Alloantibody and autoantibody monitoring predicts islet transplantation outcome in human type 1 diabetes. Diabetes (2012) 0.99
Can liver transplantation provide the statistical cure? Liver Transpl (2013) 0.98